



Mallinckrodt Baker

COVIDIEN LAUNCHES PANEXCEA™ PERFORMANCE EXCIPIENT

PanExcea MCC333G is the first product in the new performance excipients platform

Phillipsburg, New Jersey - July 9, 2008 - Covidien (NYSE: COV, BSX: COV), a leading global provider of healthcare products, today announced that its Mallinckrodt Baker business unit is introducing PanExcea MCC333G performance excipient. PanExcea MCC333G is a homogeneous particle that serves as a filler, binder and disintegrant for immediate release applications. Manufactured using novel particle engineering technology, the granular spherical excipient provides multifunctional performance capabilities which enable efficient and cost effective drug development and manufacturing.

PanExcea MCC333G lowers the total cost of ownership for the drug formulator by facilitating direct compression of even the most difficult Active Pharmaceutical Ingredients (APIs). It offers extensive API compatibility and variable API load capability to increase formulation flexibility. PanExcea MCC333G, which can be used as a building block or as a complete excipient, provides formulation development flexibilities and efficiencies, and it also enables implementation of Quality by Design initiatives.

“J.T.Baker PanExcea performance excipients are Mallinckrodt Baker’s entry into the global performance excipient marketplace. We are proud to introduce this new technology, which allows our customers to simplify drug formulation development and reduce supply chain complexities,” said Patrick Henry, global marketing manager, pharmaceutical excipients for Mallinckrodt Baker.

Customers interested in learning more about the new PanExcea product line should call 1-800-943-4747 to collaborate with a Mallinckrodt Baker applications engineer. Customers

can also visit www.mallbaker.com/panexcea to request a qualification sample.

Mallinckrodt Baker will be featuring the new PanExcea product line at its booth at the CPhI Show in Frankfurt, Germany, on September 30 – October 2, 2008.

ABOUT MALLINCKRODT BAKER

Mallinckrodt Baker is a manufacturer of high purity chemicals and related products and services sold under two well-known and respected brand names - J.T.Baker® and Mallinckrodt® Laboratory Chemicals. These products are widely used in research and quality control laboratories, microelectronics, environmental testing laboratories and universities, and for manufacturing in the pharmaceutical, biotechnology, and other industrial markets. Based in Phillipsburg, New Jersey, Mallinckrodt Baker is part of Covidien.

ABOUT COVIDIEN

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in four segments: Medical Devices, Imaging Solutions, Pharmaceutical Products and Medical Supplies. With 2007 revenue of nearly \$9 billion, Covidien has more than 42,000 employees worldwide in 57 countries, and its products are sold in over 130 countries. Please visit www.covidien.com to learn more about our business.

Contacts Erica Abbett
Media Relations Manager
314-654-3247
erica.abbett@covidien.com

Coleman Lannum, CFA
Vice President, Investor Relations
508-452-4343
cole.lannum@covidien.com

Trademarks are owned by Mallinckrodt Baker, Inc. unless otherwise noted.
Mallinckrodt® is a trademark of Mallinckrodt Inc.